1Y Annualised Return
▲29.43%
3Y Annualised Return
▲33.15%
5Y Annualised Return
▲30.41%
Cohance Lifesciences Stock Performance
|
|
|
Cohance Lifesciences Company background
Founded in: 2018
Managing director: Venkatanaga Kali Vara Prasad Raju Vetukuri
Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors. The Companys comprehensive services encompass Custom Synthesis, Process RD,ScaleUp, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process RD, scaleup and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.During the year 201920, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS Business Undertaking Division to the Company through the Scheme of Arrangement (Demerger) approved by the Honble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company. In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/ (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/ (Rupee One only) each held by each shareholder in the Demerged Company (SLSL) as on the Record Date (i.e., 22nd January, 2020), thereby resulted in a mirror shareholding of SLSL in the Company. The equity shares of the Company were listed to trade w.e.f. 09th March, 2020.The Board of Directors in its meeting held on August 17, 2020 considered, approved and recommended an issue of bonus shares in the proportion of (1:1) one new equity share of the Company of Re 1 each for every one existing equity share of the Company of Re 1 each.The company has a massive Rs 320crore capex plan. Suven has invested Rs 120 crore in 201920. The balance is to be invested in 202021.During the year 201920, the Company invested USD35 million in Rising Pharma Holdings, Inc., USA through its wholly owned subsidiary, Suven Pharma, Inc., USA. Suven Pharma, Inc., in USA was originally formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period now integrated with CDMO business of the Company, as per the decisions taken by the Board of the Company and of the Demerged Company i.e., Suven Life Sciences Ltd, in accordance with the enabling provisions of Scheme of Arrangement as sanctioned by Honble NCLT Hyderabad Bench. As a result, Suven Pharma, Inc., in USA has become wholly owned subsidiary of the company during the FY 20192020.As on 31 March 2020,the company has one subsidiary and one associate company under its roof.The company filed 11 ANDAs as on March 31, 2020 and three of those secured the green light from the regulator.The Board has allotted the Bonus shares at 1:1 ratio in its Board Meeting held on 29 September 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956..In 2022, the Company filed 17 ANDAs of which 9 had received approvals and 8 products were launched up to March, 2022.During year 2022, Company acquired 100% stake in Casper Pharma Private Limited, a Hyderabad based SEZ unit and Casper Pharma became a Wholly Owned Subsidiary of the company.
As of 21 Jul, 2025, Cohance Lifesciences share price is ₹1070.6. The stock opened at ₹1077 and had closed at ₹1083.4 the previous day. During today’s trading session, Cohance Lifesciences share price moved between ₹1,057.85 and ₹1,081.10, with an average price for the day of ₹1069.47. Over the last 52 weeks, the stock has recorded a low of ₹815.05 and a high of ₹1,360.00. In terms of performance, Cohance Lifesciences share price has declined by 0.2% over the past six months and has increased by 29.43% over the last year.
Cohance Lifesciences SIP Return Calculator
Over the past
1 year
3 years
5 years
Total Investment of ₹65,00,000
Would have become ₹75,61,251 (+16.33%)
Daily SIP of ₹25,000 would have become ₹75,61,251 in 1 year with a gain of ₹10,61,251 (+16.33%)
Cohance Lifesciences Fundamental
Market Cap (in crs)
40,959.55
Face Value
1
Turnover (in lacs)
913.40
Key Metrics
Qtr Change %
31.36% Gain from 52W Low
-8.3
Dividend yield 1yr %
0
Cohance Lifesciences Key Financials
Loading chart...
Loading chart...
Loading chart...
Loading chart...
Cohance Lifesciences Quarterly Revenue
| Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|
402.02 Cr | 307.15 Cr | 257.72 Cr | 230.69 Cr | 252.93 Cr |
Cohance Lifesciences Yearly Revenue
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
1256.14 Cr | 1113.26 Cr | 1386.69 Cr | 1412.6 Cr | 1023.96 Cr | 851.91 Cr |
Cohance Lifesciences Quarterly Net Profit/Loss
| Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|
38.73 Cr | 83.29 Cr | 81.98 Cr | 60.77 Cr | 53.37 Cr |
Cohance Lifesciences Yearly Net Profit/Loss
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
264.77 Cr | 300.28 Cr | 411.29 Cr | 412.69 Cr | 308.61 Cr | 268.79 Cr |
Cohance Lifesciences Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
1071.90
Current Price
5Day EMA
1,068.30
10Day EMA
1,050.10
12Day EMA
1,044.70
20Day EMA
1,032.50
26Day EMA
1,030.10
50Day EMA
1,040.00
100Day EMA
1,066.40
200Day EMA
1,060.90
5Day SMA
1,074.30
10Day SMA
1,040.50
20Day SMA
1,013.60
30Day SMA
1,008.60
50Day SMA
1,030.70
100Day SMA
1,088.90
150Day SMA
1,096.00
200Day SMA
1,138.00
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 35434 Rs | 88467 Rs |
Week Rs | 228868 Rs | 329804 Rs |
Month Rs | 184419 Rs | 314512 Rs |
Resistance & Support
1,069.87
Pivot
Resistance
First Resistance
1,081.88
Second Resistance
1,093.12
Third Resistance
1,105.13
Support
First Support
1,058.63
Second support
1,046.62
Third Support
1,035.38
Relative Strength Index
59.04
Money Flow Index
80.32
MACD
14.56
MACD Signal
2.51
Average True Range
35.52
Average Directional Index
25.09
Rate of Change (21)
8.92
Rate of Change (125)
-0.82
Cohance Lifesciences Peer comparison
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
26,292.81 | 1385.75 | 2030 | 1,654.10 | 2.86% | -4.95% | -6.02% | -5.90% | 100.85% | 0.92% | 41.57 | 43.65 | 7.79 | ||
28,158.75 | 750 | 1868.8 | 1,773.90 | -4.61% | 0.13% | 29.37% | 123.14% | 681.86% | 0.00% | 0.00 | 43.65 | 10.21 | ||
672.00 | 27,039.25 | 599.55 | 960.6 | 657.25 | 5.46% | 6.31% | -19.36% | -10.54% | 12.05% | 0.19% | 62.65 | 49.57 | 5.83 | |
33,177.00 | 1277.8 | 2220.95 | 2,000.30 | 6.57% | 16.84% | 21.37% | 1.16% | -13.56% | 0.89% | 30.42 | 43.65 | 3.40 | ||
211.84 | 28,140.18 | 145.25 | 307.9 | 211.18 | 1.84% | 8.51% | -12.12% | 43.14% | 0.00% | 0.07% | 40.79 | 43.65 | 3.77 | |
25,733.34 | 889 | 1580 | 1,367.20 | 0.20% | 3.47% | 0.05% | 0.48% | 0.00% | 0.22% | 81.14 | 43.65 | 8.51 |
Cohance Lifesciences Share Price FAQs
What is Share Price of Cohance Lifesciences ?
Cohance Lifesciences share price is ₹1071.90 in NSE and ₹1072.80 in BSE as on 21/7/2025.
How has Cohance Lifesciences shares performed in the past ?
Cohance Lifesciences share price in the past 1-year return was 30.47. The Cohance Lifesciences share hit a 1-year low of Rs. 815.05 and a 1-year high of Rs. 1360.
What is the market cap of Cohance Lifesciences ?
The market cap of Cohance Lifesciences is Rs. 40959.55 Cr. as of 21/7/2025.
What is the current P/E ratio of Cohance Lifesciences ?
The PE ratios of Cohance Lifesciences is 150.9 as of 21/7/2025.
What is the current PB ratio of Cohance Lifesciences ?
The PB ratios of Cohance Lifesciences is 17.6 as of 21/7/2025
What is the Mutual Fund shareholding in Cohance Lifesciences ?
The Mutual Fund Shareholding in Cohance Lifesciences was 8.65% at the end of 21/7/2025.
How to buy Cohance Lifesciences shares?
You can easily buy Cohance Lifesciences shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
What is the 52-week high and low of Cohance Lifesciences ?
The 52-week high and low of Cohance Lifesciences share price is ₹1360 and ₹815.05 as of 21/7/2025.
Please be aware that Cohance Lifesciences stock prices are subject to continuous fluctuations due to various factors.
Open Demat Account